Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Chief Scientific Officer | July 21, 2026 | July 23, 2026 |
| EQRx, Inc.CMLT · Entity 108311 | Director | April 06, 2021 | April 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date July 21, 2026 · Filed July 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 812,058 |
Ending reported balance
After 2026-07-21 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-07-21 · Exercise / conversion · Acquired 284,800 · Balance 1,304,458 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. Row 2 · 2026-07-21 · Sale · Disposed 278,698 · Balance 1,025,760 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.90 to $21.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Row 3 · 2026-07-21 · Sale · Disposed 213,702 · Balance 812,058 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.55 · Expires 2028-02-07 | Direct | 0 |
Reported balance
After 2026-07-21 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-21 · Exercise / conversion · Disposed 284,800 · Balance 0 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026. F4: The option was fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2026.
F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.90 to $21.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.90 to $22.47, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F4: The option was fully vested and exercisable.
EQRx, Inc.
Report date April 06, 2021 · Filed April 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B common stockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-04-06 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-253475) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Class B common stock will automatically convert into shares of Class A common stock at the time of the issuer's initial business combination or earlier at the option of the holder as described under the heading "Description of Securities--Founder Shares" in the Issuer's registration statement on Form S-1 (File No. 333-253475) (the "Registration Statement"), on a one-for-one basis, subject to adjustment for stock splits, stock capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2020 Filed Feb 20, 2020 21:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-011075 · doc4.xml · derivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 570,400 Underlying: Common Stock · 18,500 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 18,500 | $31.38 | $580,530.00 |
DisclosureSEC source: 0001209191-20-011075 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $30.93 to 31.72 inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 21:30 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 18,500 | $6.32 | $116,920.00 |
DisclosureSEC source: 0001209191-20-011075 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 12:05 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $31.71 | $0.00 |
DisclosureSEC source: 0001209191-20-009870 · doc4.xml · derivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| January 17, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,700 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · derivative · entry 14 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,900 Underlying: Common Stock · 3,700 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 17, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,400 | $28.30 | $67,920.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 9 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.09 to 28.66, inclusive. Read SEC document |
| January 17, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,300 | $27.33 | $35,529.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 8 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,079 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $27.11 to 27.89, inclusive. Read SEC document |
| January 17, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,700 | $6.32 | $23,384.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 7 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| January 16, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,700 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · derivative · entry 13 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 592,600 Underlying: Common Stock · 3,700 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 16, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,300 | $29.54 | $38,402.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 6 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.40 to 29.69, inclusive. Read SEC document |
| January 16, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,300 | $28.98 | $37,674.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 5 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,979 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $28.40 to 29.39, inclusive. Read SEC document |
| January 16, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,100 | $27.80 | $30,580.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,279 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $27.39 to 28.31, inclusive. Read SEC document |
| January 16, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,700 | $6.32 | $23,384.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 3 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,700 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · derivative · entry 12 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 596,300 Underlying: Common Stock · 3,700 shares Expires 2025-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 3,700 | $29.52 | $109,224.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 2 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $29.25 to 29.74, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 22:29 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 3,700 | $6.32 | $23,384.00 |
DisclosureSEC source: 0001209191-20-004113 · doc4.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,379 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 21:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionSeries E-1 Preferred Stock · Derivative | 70,679 | $0.00 | $0.00 |
DisclosureSEC source: 0001572426-19-000088 · primary_doc.xml · derivative · entry 4 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,679 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Reflects automatic conversion of Series E-1 Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F1 · derivative.exercise_date: Reflects automatic conversion of Series E-1 Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F1 · derivative.expiration_date: Reflects automatic conversion of Series E-1 Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 21:01 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | ConversionCommon Stock | 70,679 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001572426-19-000088 · primary_doc.xml · nonDerivative · entry 1 ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Reflects automatic conversion of Series E-1 Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. F1 · price: Reflects automatic conversion of Series E-1 Preferred Stock into common stock on a one-for-one basis upon the closing of the initial public offering of Issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.